Imagene AI was founded in 2020 with a clear mission to empower physicians with immediate oncology intelligence to facilitate optimal treatment for more cancer patients. We leverage AI to profile, within minutes, a broad range of cancer biomarkers from the biopsy image alone. By doing so we can overcome economical, logistical, and technological barriers to reach the full potential of precision medicine for cancer patients.
Imagene was recognized by Frost & Sullivan for the 2023 "Technology Innovation Leadership Award in AI-based molecular testing for cancer diagnosis", and won the 2023 Digital Health Award for "Best use of AI".
Our success derives from our cutting-edge technology and a multidisciplinary team of data scientists, biologists, software engineers, and medical experts.
Cancer diagnosis relies heavily on pathological and molecular testing, both conducted through advanced technology. However, the limited availability of tissue samples restricts extensive and comprehensive diagnoses. Moreover, the cost of genomic analysis, infrastructure, and skilled personnel poses a significant financial burden and resulting in long turnaround times. Addressing these challenges, AI-based algorithms hold the key to substantial improvements.
At Imagene, we firmly believe that no structural or financial barriers should hinder personalized treatment. That's why we are dedicated to unlocking the potential of rapid accurate, and standardized molecular profiling for all cancer patients.